0000000000033861
AUTHOR
Michael Schaffrath
Heterocyclisch anellierte Steroide aus 2-Hydroxymethylen-canrenon
A-ring annulated heterocycles, the isoxazole 6, the pyrazoles 8 and the pyrimidines 9 are prepared starting from 2-hydroxymethylene canrenone 1. Binding studies were carried out with the compounds 1 and 6-8 using estrogen, progesterone, androgen, gluco- and mineralocorticoid receptors as well as the serum proteins SHBG and CBG: the substances were inactive on the receptor level. 1, 7 and 8a show weak binding affinity to CBG.
Darstellung und Reaktionen von 2-Methylen-canrenon
Ausgehend vom Mannich-Salz 1 des Aldosteronantagonisten Canrenon oder von 2-Methylen-canrenon (2) wurden die am A-Ring anellierten Hetero- und Carbocyclen 5, 6, 8–13 dargestellt. Mit den Verbindungen 2, 3, 4b, 5, 6b, 8 und 12 wurden Bindungsstudien am Estradiol-, Progesteron-, Androgen-, Glucocorticoid- und Mineralocorticoid-Rezeptor sowie an den Serumproteinen Sexualhormonbindendes Globulin (SHBG) und Corticosteroidbindendes Globulin (CBG) durchgefuhrt. Die relativen Bindungsaffinitaten lagen bei CBG unter 1%, in allen anderen Fallen niedriger als 0.01%. Synthesis and Reactions of 2-Methylene-canrenone Starting from the Mannich salt 1 of the aldosterone antagonist canrenone or from 2-methy…
Zur Acetylierung von Spironolacton, Canrenon und 2-Methylencanrenon
Bei der Umsetzung der Titelverbindungen mit Acetanhydrid und Acetylchlorid werden das 3,5-Dien-3-yl-acetat 2, die isomeren 2,4,6- und 3,5,7-Trien-3-yl-acetate 3 und 4 sowie das 2,4,6,8(14)-Tetraen-3-yl-acetat 7 erhalten. Hydrolyse von 7 liefert das 2α-Methl-8,14-didehydro-canrenon (9). 7 und 9 wurden auf ihre Bindungsfahigkeit gegenuber Hormon-Rezeptoren sowie den Serumproteinen SHBG und CBG gepruft: Die Substanzen erwiesen sich als inaktiv. Acetylation of Spironolactone, Canrenone, and 2-Methylene Canrenone Reaction of the title compounds with acetic anhydride and acetyl chloride yields the 3,5-dien-3-yl acetate 2 the isomeric 2,4,6- and 3,5,7-trien-3-yl acetates 3 and 4 as well as the 2,4…
Concentrations of ovarian proteohormones as biological markers for the outcome of assisted reproductive technology
Objective: To assess whether the ovarian proteohormones inhibin A and B, pro-alpha-C and activin A could act as direct biological markers of a poorer or better response to ovulation induction or clinical conception through assisted reproductive technology (ART). Methods: Seventy-seven women who underwent ART were included in the study and were divided into two groups: (i) 46 women with sonographically documented follicular maturation; and (ii) 36 women who demonstrated inadequate follicle development. Blood samples were analyzed for inhibin A, inhibin B, pro-alpha-C, activin A and estradiol (E2) at day 3 of stimulation with recombinant follicle-stimulating hormone (rFSH) after pituitary dow…
Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in women with idiopathic premature ovarian failure.
Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in 30 women with idiopathic premature ovarian failure (POF), 30 postmenopausal women, and 30 age-matched fertile women were determined. Women with POF showed low levels of inhibin A and inhibin B, but not of activin A, whereas the levels of pro-alphaC were significantly higher than in postmenopausal women. Thus, the circulating level of pro-alphaC could be a marker for assessing residual ovarian function in women with POF.
Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment
To investigate the influence of human recombinant follicle-stimulating hormone (FSH) on circulating serum concentrations of the ovarian proteohormones inhibin A, inhibin B, pro alpha-C, and activin A and serum levels of estradiol after down-regulation with GnRH analogue.Serum concentrations of ovarian proteohormones and estradiol.Academic clinical practice.30 women who underwent assisted reproductive techniques.Blood samples were analyzed for inhibin A, inhibin B, pro alpha-C, activin A, and estradiol during IVF treatment at points coinciding with pituitary down-regulation, stimulation with recombinant FSH, ovulatory triggering, and the luteal phase of the cycle.Activin A levels did not cha…
The effect of cancer treatment on female fertility and strategies for preserving fertility.
Aggressive chemotherapy and radiotherapy in young patients with cancer has greatly enhanced the life expectancy of these patients, but these treatments often cause infertility because of the massive destruction of the ovarian reserve resulting in premature ovarian failure (POF). This review focuses on the effect of cancer treatments on fertility and on the various surgical and assisted-reproduction innovations that are available to provide the patient with the option of future pregnancies. As the emerging discipline of fertility preservation is steadily attracting increasing interest, developments in the near future promise to be very exciting. However, in everyday routine work, better inte…